enlarged deposits of positive reactive microglia (HLA-DR) in substantia nigra and abridged cortical activity of choline acetyltransferase, 6 inclusions of brain alpha-synuclein positive, 7 accumulation of iron in neurofibrillary tangles and senile plaques contributes in the formation of oxygen radicals and inducing oxidative stress. 8, 9 Cognitive impairment in executive function, language, visuospatial function, episodic and semantic memory are related with tau pathology (as measured by 18 F-AV-1451 binding in temporal, fronto-parietal, occipitotemporal brain regions) and grey matter atrophy ( 11 C-PiB uptake) observed through positron emission tomography. 10 Loss of frontal and parietal synaptic density is considered as a major correlate of cognitive impairment in AD. 11 Number of neurofibrillary tangles in entorhinal cortex, area 9 and CA1 are predictors of cognitive impairment. 12 Demyelinations of subcortical white matter and periventricular area are determinants of cognitive decline in AD. 13 Huperzine-A is a natural sesquiterpene alkaloid compound extracted from Huperzia Serrata (Chinese herb) which acts a reversible acetylcholinesterase (enzyme that break downs acetylcholine) inhibitor by crossing blood-brain barriers. Huperzine-A as a dietary supplement is efficacious in improving cognitive status and activities of daily living in patients with AD.
14 Huperzine-A is an alkaloid with neuroprotective properties. Animal studies have demonstrated that Huperzine-A acts as protective agent countering organophosphate (OP) intoxication eventually reducing glutamate-induced cell death. 15 Huperzine-A has stronger penetration in blood brain barrier, prolonged duration of acetylcholinesterase inhibitory action and greater bioavailability than other cholinesterase inhibitors (donepezil, rivastigmine, and tacrine). Huperzine-A has cognitive enhancing properties by protecting against several pathological factors inducing neurodegeneration such as beta-amyloid protein (or peptide), ischemia, hydrogen peroxide, glutamate, apoptosis and staurosporine-induced cytotoxicity. As a result, oxidative stress is reduced, expression of apoptotic proteins (Bcl-2, Bax, P53, caspase-3) gets regulated, protection of mitochondria and interference with amyloid precursor protein metabolism occurs, nerve growth factor and its receptors is up-regulated. 16 Pharmacological studies have shown that Huperzine-A goes beyond inhibition of acetylcholinesterase, it can improve learning and memory deficits both in animal models and patients with AD. 17 Twelve to eight week use of Huperzine-A can improve mental status as assessed through Mini Mental State Examination. 18 Twelve week use of Huperzine-A significantly improved cognition, behavior, activities of daily living, and mood in AD patients. 19 Task switching is an higher order executive function which rely on frontoparietal network. Research has shown that patients with AD have task switching deficits. Such deficits cannot be improved with practice in AD patients. 20 These patients were deficient in inhibition, cognitive flexibility, self-monitoring and attentional control. 21, 22 However, there is still a gap in literature to understand whether huperzine-A is efficacious in improving task switching deficits and major cognitive domains (memory, language, attention/orientation, fluency, visuo-spatial function). It was hypothesized that (i) Patients with AD would show cognitive and task switching deficits in contrast with healthy individuals (ii) Huperzine-A would significantly improve cognitive and task switching deficits in AD patients.
METHODS
Fifty patients diagnosed with AD according to DSM-5 23 at Civil and BV hospital Bahawalpur, and Nishter hospital Multan, Pakistan during May 2017 until February 2018 participated in the study. The inclusion criterion for patient group were as follows: (i) age above 50 (ii) mild/moderate dementia screened through Mini Mental State Examination-MMSE 13-24 24 (iii) not having depression as screened through Geriatric Depression Scale score 0-4 25 (iv) not recommended any steroids, stimulants and nootropics by the physician (v) not having any concomitant medication (vi) no comorbid conditions. Exclusion criterion were: (i) physical and psychiatric disorder other than AD (ii) non AD dementia. Fifty healthy individuals took part in the study. Inclusion criterion were: (i) having normal cognition MMSE-score 24-30 24 (ii) no depression-score 0-9 25 (Table 1) . No adverse effect of the drug was reported by any patient. Thus, there was no drop out of patients from the study. 26 TMT is a two part neuropsychological measure of visual attention (part A) and task switching (part B). In part A, participant is instructed to connect series of numbers following a sequence whereas in part B the requirement is to connect an alternating series of numbers-letters such as 1A2B3C…. Time to perform the test is recorded (Part A average time 29 s deficient >78 s; Part B average time 75 s deficient >273 s). 27 ACE-III is a valid and reliable measure to assess cognitive impairment in patients with AD. It is assesses five cognitive domains: visuospatial skills, attention/orientation, verbal fluency, language, and memory. Cut-off to assess intact cognition is 88/100; higher score shows better cognition.
Trail Making Test (TMT)

Addenbrooke's Cognitive Examination (ACE-III)
Procedure
The study was approved by the board of studies of The Islamia University of Bahawalpur, Pakistan. Participants and caregivers of patients gave written informed consent. Healthy individuals has single testing session whereas patients were assessed twice: (i) at the time of diagnosis (ii) post-eight weeks medication of Huperzine-A oral dose of 0.2 mg twice a day. Clinical psychologist who conducted testing sessions and participants were blinded to the objectives of the study. Testing of measures TMT and ACE-III were completely randomized across participants. In addition, fundamental skills were assessed through instrumental activities of daily living scale. 28 Participants were debriefed about objectives of the study at the end of testing session and were thanked for their participation.
RESULTS
Statistical analysis was conducted through SPSS (version 20).
Data on demographic variables showed that patients with AD were not different from healthy individuals on age and socio economic status. Sample had equal ratio of male and female (Table 1) . Table 1 Characteristics of sample (n = 100). Table 3 ).
AD Group Control Group
DISCUSSION
The present study was designed to assess efficacy of Huperzine-A on cognition and task switching. The study yielded several important results: (i) patients with AD showed deficient performance in various cognitive domains in contrast with healthy individuals (ii) AD patients were slower to perform visual attention and switching tasks compared with healthy individuals. In contrast, healthy individuals showed efficient performance on both parts of TMT (iii) After eight weeks of Huperzine-A treatment of AD patients, there was a significant difference between baseline and post-treatment scores on ACE and TMT. AD patients showed significant improvement in cognitive domains. Post-treatment reaction times on both parts of TMT were significantly reduced.
Deficient cognitive performance can be seen in the context of pathological factors involved in AD onset for instance neurofibrillary tangles and neuritic plaques in cognition related brain areas (frontal, temporal, parietal lobes), 3, 12 lesions of cerebral cortex weakening interconnections between cortical and subcortical brain regions, 4 tau pathology in neocortical neurons, 5 accumulated positive reactive microglia in substantia nigra and accelerated choline acetyltransferase, 6 alphasynuclein positive deposition, 7 oxidative stress, 8, 9 grey matter atrophy, 10 reduced synaptic density in frontal and parietal lobes, 11 demyelination of subcortical white matter and periventricular areas. 13 Our findings of improved cognition and task switching abilities in AD patients post-Huperzine-A treatment are consistent with previous studies showing improved mental status post eight weeks of Huperzine-A treatment. 18 Longer use of Huperzine-A, for instance twelve weeks can improve mood, behavioral problems, activities of daily living and cognition in AD patients. 19 Huperzine-A is a reversible acetylcholinesterase inhibitor which has neuroprotective characteristics. Animal model studies demonstrated its' countering effects on OP intoxication by reducing glutamate induced cell death. 15 Other studies have shown that Huperzine-A improves cognition acting against cytotoxicity induced by beta-amyloid protein, apoptosis, ischemia, staurosporine and hydrogen per oxide. This mechanism reduces oxidative stress, protects mitochondria, interrupts metabolism of amyloid precursor protein, and regulates apoptotic protein expression, nerve growth factor and its' related receptors. 17 This study has a few limitations. Concerning the slow progressive nature of AD, six months may be a not long enough to observe the effects of Huperzine-A medication. It may also be difficult to differentiate from the placebo effects. Therefore, further investigation is needed to confirm this preliminary evidence. In conclusion, results of the current study have implications in every day clinical practice. Apart from other cognitive domains, task switching is an important ability to maintain daily life functioning. The study highlights that Huperzine-A is an effective therapeutic treatment to improve such dynamic human abilities in patients with AD.
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